Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer
2003; Elsevier BV; Volume: 14; Issue: 3 Linguagem: Inglês
10.1093/annonc/mdg106
ISSN1569-8041
AutoresD. Y. Kim, Jung Ho Kim, S.-H. Lee, T.Y. Kim, Dae Seog Heo, Yung‐Jue Bang, N. K. Kim,
Tópico(s)PI3K/AKT/mTOR signaling in cancer
ResumoBackgroundOxaliplatin shows preclinical activity in many cancer cell lines that are resistant to cisplatin, and also has synergism with 5-fluorouracil (5-FU). We undertook this study to evaluate the efficacy and toxicities of a combined oxaliplatin, 5-FU and leucovorin (LV) continuous infusion regimen in patients with advanced gastric cancer who progressed during or after treatment with 5-FU and platinum compounds.Patients and methodsTwenty-six patients with advanced gastric cancer, whose disease progressed while receiving, or after discontinuing, chemotherapy with a 5-FU and platinum regimen, were enrolled in this study. Treatment comprised oxaliplatin (85 mg/m2 on day 1) as a 2-h infusion followed by bolus 5-FU (400 mg/m2 on day 1), and 48-h infusion of 5-FU 2.4–3.0 g/m2 concurrently with LV 150 mg/m2. Cycles were repeated at2-week intervals.ResultsOf the 23 evaluable patients, there were six partial responses (response rate 26%). All responding patients were among those who entered into this trial immediately after failure of previous chemotherapy with 5-FU and cisplatin. The median time to progression was 4.3 months and the median overall survival was7.3 months. The most common hematologic toxicity was grade 1–2 anemia in 39 cycles (39%). No grade 4 leukopenia or thrombocytopenia were observed. The most common non-hematologic toxicity was nausea/vomiting (33%). Peripheral neuropathy of grade 1 or 2 was noted (27%), but there was no grade 3 or 4 neurotoxicity.ConclusionsThis phase II study of oxaliplatin, 5-FU and LV continuous infusion showed activity in previously platinum-treated patients with advanced gastric cancer, with acceptable toxicities.
Referência(s)